Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma

Su Li,1,2 Dongsheng Zhang,1,3 Jian Sun,1,2 Zhinming Li,1,3 Liting Deng,1,2 Benyan Zou,1,3 Jing Zhan1,2 and Wenqi Jiang1,3,*

1State Key Laboratory of Oncology in Southern China; Sun Yat-Sen University; Guangzhou, Guangdong China; 2Department of Clinical Trial Center; Cancer Center; Sun Yat-sen University; Guangzhou, Guangdong China; 3Department of Medical Oncology; Cancer Center; Sun Yat-Sen University; Guangzhou, Guangdong China

Keywords: anti-CD22 monoclonal antibody, tolerance, pharmacokinetics

Introduction

Non-Hodgkin lymphomas (NHLs), a heterogeneous group of cancers principally arising from B lymphocytes, represent approximately 40% of newly diagnosed cancers, and are characterized by expression of lineage-specific B cell antigens, such as CD19, CD20 and CD22.1 Aggressive NHL comprises approximately 30–40% of adult NHL, and indolent (or low-grade) B-cell lymphomas represent approximately 40% of NHLs.2 Effective treatments for indolent lymphomas include radiotherapy, single-agent therapy or combination chemotherapy and the response rate is in the range of 60–80% for first-line therapy.3 Patients with aggressive NHL have high response rates to the front-line combination chemotherapy regimen of cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP),\textsuperscript{4,6} but disease recurs and becomes resistant to treatment in most patients.

The successful use of monoclonal antibodies (mAbs) in the treatment of human disease has increased steadily in the past two decades. Rituximab, a human-mouse chimeric anti-CD20 immunoglobulin (Ig)\textsubscript{G\textsubscript{1}}, was approved in 1997 in the United States as the first mAb used in combination with chemotherapy for first and subsequent lines of treatment for lymphoma.\textsuperscript{7,8} However, a subgroup of patients does not respond, and early relapses occur in patients with initial response. There is thus a clear need to explore alternative antibodies that are non-cross resistant to rituximab as therapy for B-NHL. One alternative is to explore new antibodies targeting B-cell antigens such as CD22; two such mAbs, epratuzumab (a humanized anti-CD22 IgG1), and inotuzumab ozogamicin (a humanized anti-CD22 IgG4 conjugated to calicheamicin), are currently in clinical studies.\textsuperscript{9-12} CD22 is a 135-kDa B lymphocyte restricted type-I transmembrane sialoglycoprotein of the immunoglobulin superfamily, with seven Ig-like domains and three cytoplasmic immunoreceptor tyrosine-based inhibition motifs.\textsuperscript{13} CD22 is expressed in mature B cells, but not in their precursor or memory B cells.\textsuperscript{13,14} It is strongly expressed in follicular, mantle and marginal-zone B cells, but is weakly present in germinal B cells, thus indicating its potential therapeutic target for B-NHL.\textsuperscript{15} The function of CD22 has not been entirely clarified; it acts as a homing receptor for recirculating B cells through the affinity of the lectin-like domains for 2,6-linked sialic acid-bearing glycans and as a B-cell antigen receptor (BCR) down-modulating co-receptor.\textsuperscript{16}

In early clinical studies of epratuzumab (Immunomedics, Inc.,), single-agent activity was shown in patients with aggressive NHL and indolent NHL. Monotherapy was found to be well-tolerated, and there was evidence of clinical activity when western Caucasian patients with NHL were administered doses from 120–1,000 mg/m\textsuperscript{2} and, specifically, at the 360 mg/m\textsuperscript{2} dose used for a Phase 2 clinical trial.\textsuperscript{17} It is suggested that biological agents do not necessary have optimal activity at the maximally tolerated dose. If toxic effects are mediated by a mechanism distinct from that of antitumor action, increasing doses to toxic levels would not be necessary to achieve efficacy. This is especially important for relatively nontoxic agents such as antibodies because the ultimate goal of early clinical studies is to identify an optimal dose. Based on preclinical studies, the optimal dose was defined as the dose at which B cells were completely saturated such that maximal inhibition of tumor growth would be achieved. It has been suggested that complete saturation of the B-cell binding might be associated with a plateau of systemic clearance of antibody, but the published pharmacokinetic data describing the behavior of antibodies targeted to CD22 in man are limited.\textsuperscript{17,18}

However, no antibodies targeted to CD22 have been evaluated in Chinese patients with NHL as yet. SM03 is a recombi- nant, human/mouse chimeric IgG1 mAb directed against CD22 antigen on human B lymphocytes. It is composed of Fv regions of a murine anti-CD22 antibody with human Ig G\textsubscript{1}, heavy, with molecular weight of 148 KD, produced by Shenzhen Lonn Ryonn Pharmaceutical Co., Ltd., SM03 is expressed in ST20 cell, which is stably transfected murine myeloma cell line (SP2/0). We compared the affinity the in vitro and in vivo biological activities of these two antibodies. The vitro assays showed SM03 had the same high affinity (0.82 nM) against CD22 antigen as epratuzumab, and also demonstrated reactivity antibody with 50 of 51 B cell NHL specimens tested, but not with other malignancies or normal non-lymphoid tissues CD19 and CD20 antigens (data not shown).

We describe here the safety, clinical activity, pharmacokinetics and immunogenicity of SM03 in Chinese patients with NHL. Effects on blood mononuclear cells, Ig levels, aminotransferase and other laboratory parameters were assessed. SM03 was administered as four once-weekly infusions at doses from 60–480 mg/m\textsuperscript{2} to patients with NHL and, based on the results, an optimal dose was chosen for further research. These data demonstrate that, although SM03 showed more adverse effects occurrence and higher incidence rate of side effects in Chinese patients compared with those observed in western Caucasian patients treated with epratuzumab, SM03 had an acceptable safety profile, exhibited clinical benefits and offers promise as a new agent with potential utility in the treatment of NHL.

Results

Demographics and baseline disease characteristics. From April 2007 to September 2008, a total of 21 patients were enrolled in the study. First, one patient was administered SM03 at a dose of 60 mg/m\textsuperscript{2}/week and monitored for infusion reactions. Dose escalation was conducted with two patients who received 120 mg/m\textsuperscript{2} in the initial cohort. Subsequently, six patients per group were treated at each of the 240, 360 and 480 mg/m\textsuperscript{2}/week dose levels. Demographic and other baseline characteristics for all patients are summarized in Table 1. There were ten males and 11 females, with median age of 54 y (range, 24–67 y). All patients had CD22-positive B-cell non-Hodgkin lymphoma and were categorized in stage II (9.5%), stage III (42.9%) and stage IV (47.6%) according to clinical staging.

Dose escalation. In dose escalation, one patient of six cohorts at the dose of 360 mg/m\textsuperscript{2}/week had dose limiting toxicity (DLT) and experienced grade 4 neutropenia for 7 d. We did not observe a maximum tolerated dose (MTD) in the dose range of 60–480 mg/m\textsuperscript{2}/week. Estimates of systemic clearance of SM03 were indicative of possible nonlinear elimination at doses >360 mg/m\textsuperscript{2}. Thus, we defined 480 mg/m\textsuperscript{2}/week as the maximum dose without dose escalation. Additional patients were treated at dose levels (2240 mg/m\textsuperscript{2}) to define a more effective dose for additional clinical trials.

Safety. All patients experienced one or more adverse event, with at least 85% of patients experiencing one treatment-related adverse effect. Most of treatment-related events were mild to moderate in severity. The major toxicities for all adverse effects were fever (71%), prolongation of activated partial thromboplastin time (PT) (42.8%), leukocytopenia (24%), neutropenia (19%), alanine transaminase elevation (24%), elevated serum creatinine (19%), injection site skin redness (14.3%). Other toxicities, regardless of whether or not they were infusion/treatment-related,
included fatigue, nausea, vomiting, tumor pain, skin rash, hypertension, hypotension, fatigue, occult blood (Table 2).

Six patients developed grade I prolongation of activated partial thromboplastin time (APTT) and one developed asymptomatic grade III prolongation treated at 360 mg/m², and needed to be supplied with intravenous coagulation factors; in all cases the APTT returned to baseline on discontinuation of SM03. Elevated transaminase (grade 1–2) occurred in six patients, three with hepatitis B virus (HBV) infection who needed orally administered heptodin to inhibit HBV replication, whereas no significant changes were seen in the number of copies of HBV. All six patients recovered during observation without supportive medication. Hematologic toxicity was usually mild and reversible. Six of 21 patients experienced leukaemia that was mild and reversible, of which five had grade I toxicity and one had grade II toxicity.

One patient experienced serious adverse effects (SAE) of gastrointestinal hemorrhage (about 300 ml blood) after 3 doses. Intravenous blood transfusion (400 ml) and fluid replacement were administered to the patient, who subsequently recovered. Another patient with a dental ulcer also experienced SAE of hemorrhage (about 5 ml) in the follow-up period. One patient discontinued treatment due to progression.

Response. When all dosing groups and histologies are considered, 15 patients (75%) of the 20 patients (excluding those who discontinued treatment) achieved stable disease as best progress, and four (20%) progressed by study day 42. However, one patient had a PR on study day 142 without interim therapy. Efficacy evaluations based on pathologic classification are detailed in Table 3. Some patients (all histologies) derived clinical benefit in the form of some amount of tumor mass reduction (Table 3). The average decrease in lesion size was 56.1% in patients achieving a PR and 2.3–48.6% in patients with stable disease (SD). Tumor size was reduced by at least 2.3% in 9 patients. Patients reported symptoms or other disease-related signs and symptoms at baseline, and symptoms resolved completely or were relived transiently in two of eight patients.

A female patient who was diagnosed with stage IV A follicular grade I lymphoma (FLIPI score 3) received treatment at a dose of 480 mg/m² SM03 for 4 consecutive cycles. On day 35, the tumor had shrunk by 23.4%, and decreased by 48.53% and 56.1% on day 72 and 142, respectively; efficacy rated as PR. A male patient, who was diagnosed with stage IEA follicular grade II lymphoma and progressed after having received anti-CD20 mAb treatment for almost 10 mo, was enrolled in the SM03 clinical trial at the dosage level of 360 mg/m² SM03. The SPD of target lesion of SPD decreased to 16.00 cm² and 14.00 cm² at day 42 and 95, respectively, which represents shrinkage by 35.35% and 43.43% in SPD.

Pharmacokinetic results. Pharmacokinetic data after four-week dosing were obtained for 19 of the 21 patients. Pharmacokinetic data for one patient who discontinued treatment during the third-dose phase due to disease progression and one patient who received at dose of 60 mg/m² were not included. A summary of the SM03 pharmacokinetic variables are presented in Figure 2.

| No. with ECOG performance scale = 0–1 (%) | 18 |
| No. with bulky disease at least 5 cm (%) | 14 |
| SPD range (cm) | 1.4–68 |
| No. with LDH >234 units/liter (%) | 9 |
| Median peripheral blood B-cell counts | 11.54 |
| CD20, cells/µl (range) | 0–33.29 |
| No. with FLIPI score = 1–2 (%) | 7 |

Table 1. Baseline demographic characteristics for patients receiving at least 1 dose of SM03

Table 2. Pharmacokinetic results.

Table 4. Following infusion of a single dose of SM03 at 120 mg/m² (n = 2), 240 mg/m² (n = 6), 360 mg/m² (n = 6) or 480 mg/m² (n = 6), levels of SM03 in serum reached a maximum at ~3 h and then declined slowly (Fig. 2). The observed maximum serum concentration after each dose increased slightly from dose 1 through dose 4 at all dose levels, consistent with an accumulation ratio of 3 for area under the curve (AUC). Cₘₙₘₙ varied greatly across individuals and ranged from 2.16% to 93.35% and related to tumor burden, circulating tumor cells and CD22 antigen in the circulation of the patients.

Mean maximum observed SM03 concentrations (Cₘₙₘₙ) and mean area under the concentration-time curve from time zero to infinity (AUCₘₙₘₙ) increased in a generally dose-proportional manner up to 360 mg/m². The data for Cₘₙₘₙ and AUCₘₙₘₙ were in keeping with this observation in that the Cₘₙₘₙ and AUCₘₙₘₙ increased by an order of magnitude between patients treated at 360 and 480 mg/m², an indication that at doses of SM03 up to 360 mg/m², the B cells in circulation may be saturated with SM03. Mean Cₘₙₘₙ values of 196.03 and 569.05 µg/ml and AUCₘₙₘₙ values of 16.81 and 41.52 µg-h/ml were distinguishable for the 360 and 480 mg/m² dose group, respectively (Fig. 3).

Mean terminal half-life (t₁/₂) ranged from (175.85 ± 32.44) to (215.47 ± 128.58) h across the 120 to 480 mg/m² doses. The mean total body clearance based on body surface area for SM03 was similar following doses from 120 mg/m² to 360 mg/m² (range, 0.01–0.013 L/h/m²), but smaller in the 480 mg/m² dose group (0.0055 L/h/m²). Mean estimates of the volume of distribution at steady-state based on body surface area ranged from 4.81, 2.57, 2.21 and 1.24 L/m² across the dose range (120, 240, 360 and 480 mg/m² SM03) and were consistent with minimal distribution of SM03 into the extravascular space.
some patients had high levels of peripheral blood B cells because of their disease and others had below-normal levels as a consequence of previous treatment, and the number of patients at each dose level was small; thus, it is not possible to draw meaningful conclusions regarding correlations between specific SM03 dose levels and peripheral blood B-cell counts. No patient developed anti-drug antibodies.

Mean serum Ig levels remained stable; no significant differences were found in IgA and IgM on Day 7, 14, 21 and 28 after dosing compared with baseline. IgG decreased on Day 7 after treatment started but returned to normal level on Day 14. No significant differences were detected on Day 21 and 28 compared with baseline (Table 5).

**Discussion**

In 1980, Nadler et al. demonstrated that a murine mAb could target human lymphoma cells and induce death in these cells.\(^{20}\) This result stimulated research that led to the development of chimeric anti-CD20 rituximab, a marketed treatment for NHL. Despite the availability of mAbs that target CD20, patients with NHL relapse or become refractory to treatment, indicating that new therapeutic agents are needed. One strategy is the development of non-cross-reactive antibodies targeting other B-cell antigens that may have different and non-overlapping mechanisms of antitumor activity. Combination therapy may result in higher antitumor activity than treatment with one drug alone. For oncology treatments, the first demonstration of combination therapy that suggested the possibility of improved efficacy involved combining epratuzumab and rituximab.\(^{23-25}\) Leonard et al. demonstrated that combination therapy with 360 mg/m\(^2\) epratuzumab and 375 mg/m\(^2\) rituximab was well tolerated and effective (with CR/Cru rates and durable remissions that appeared to exceed those reported for rituximab alone) when administered to 41 patients with indolent NHL once weekly for 4

![Figure 1. Maximum percent change from baseline in SPD for each assessable treated patient with baseline and post-baseline SPD measurements (n = 20). *Patients with absolute value of maximum percentage change ≤1. Filled triangle, SPD value >100%; open circle, patients with progressive disease as best response; no post-baseline SPD measurement available.](image)

Table 2. All adverse events with at least 5% incidence or grade ≥2 in severity over all treatment groups combined

| Preferred term                  | Weekly dose group (mg/m\(^2\)) | No. of patients with adverse events |
|---------------------------------|---------------------------------|-----------------------------------|
|                                 | 60(n = 1)                       | 120(n = 2)                        |
|                                 | 240(n = 6)                      | 360(n = 6)                        |
|                                 | 480(n = 6)                      | Total*                            |
| Fever                           | 1(100%)                         | 2(100%)                           |
| Fatigue                         | 1(17%)                          | 0(0%)                             |
| Leukocytopenia                  | 1(100%)                         | 2(33%)                            |
| Neutropenia                     | 1(100%)                         | 2(33%)                            |
| ALT elevation                   | 1(17%)                          | 1(17%)                            |
| Injection site skin redness     | 1(17%)                          | 2(33%)                            |
| Elevated serum creatinine       | 1(50%)                          | 1(17%)                            |
| APTT                             | 1(100%)                         | 2(33%)                            |

Table 3. Analysis of efficacy by different pathology classification

| Pathology                               | CR/PR | SD | PD | PD | TOTAL |
|-----------------------------------------|-------|----|----|----|-------|
| Follicular lymphoma                     | 1     | 7  | 0  | 0  | 8     |
| Diffuse large B                         | 0     | 3  | 4  | 1  | 8     |
| Follicular transformed to diffuse        | 0     | 2  | 0  | 0  | 2     |
| Small lymphocytic lymphoma/CLL           | 0     | 2  | 0  | 0  | 2     |
| Birkitt’s lymphoma                      | 0     | 1  | 0  | 0  | 1     |
| Total                                   | 0     | 16 | 4  | 1  | 21    |
patients with FL who were given the standard 4-week rituximab schedule. 25 In addition, clinical trials performed in DLBCL also showed encouraging results; a study reported that an OR rate of 47% (33% CR/CRu) was observed in 15 patients with DLBCL. Results from another trial combining these two antibodies with conventional CHOP therapy treating 15 previously untreated patients with DLBLC indicated an OR of 87% (67% CR, 20%

Figure 2. Mean (SD) serum concentrations of total SM03 after 120, 240, 360, 480 mg/m² infusion of SM03 once-weekly for 4 consecutive weeks. Filled diamond, 120 mg/m²; filled square, 240 mg/m²; filled triangle, 360 mg/m²; X, 480 mg/m².

Table 4. Pharmacokinetic Parameter Summary (120–480 mg/m² Dosage)

| Dosage | 120 mg | 240 mg | 360 mg | 480 mg |
|--------|--------|--------|--------|--------|
| Infusion | C1 | C4 | C1 | C4 | C1 | C4 | C1 | C4 |
| Tₘₐₓ (h) | 7.00 ± 5.66 | 8.00 ± 4.24 | 6.50 ± 4.11 | 7.10 ± 3.61 | 6.17 ± 3.80 | 7.67 ± 3.72 | 3.92 ± 0.86 | 23.83 ± 31.29 |
| Cₘₐₓ μ (ug/ml) | 34.7 ± 0.99 | 29.97 ± 11.59 | 126.81 ± 23.34 | 200.22 ± 60.26 | 196.03 ± 30.98 | 215.92 ± 47.42 | 569.05 ± 156.98 | 562.72 ± 229.35 |
| Λ | 0.004 ± 0.0071 | 0.07 ± 0.0016 | 0.0054 ± 0.0015 | 0.0064 ± 0.004 | 0.0051 ± 0.0018 | 0.0069 ± 0.0029 | 0.0043 ± 0.0024 | 0.001 ± 0.0016 |
| t₁/₂ (h) | 175.85 ± 32.44 | 102.33 ± 23.96 | 135.98 ± 38.85 | 137.32 ± 64.67 | 152.58 ± 55.04 | 112.9 ± 37.15 | 215.47 ± 128.58 | 70.90 ± 29.31 |
| AUC₀→ₜ (ug·ml⁻¹·h) | 2860.69 ± 105.56 | 1983.34 ± 63.16 | 10077.99 ± 311.52 | 10396.4 ± 3614.36 | 16805.39 ± 2003.02 | 15168.16 ± 4537.81 | 41523.43 ± 10506.78 | 40424.01 ± 25580.46 |
| AUC₀→∞ (ug·ml⁻¹·h) | 6305.79 ± 610.75 | 3409.92 ± 1213.31 | 19774.96 ± 8298.86 | 22157.73 ± 1551.01 | 35434.66 ± 9175.52 | 32180.2 ± 14130.49 | 129409.83 ± 97037.82 | 62655.61 ± 49517.93 |
| Vz (L) | 4.81 ± 0.42 | 5.78 ± 3.27 | 2.57 ± 0.76 | 2.40 ± 0.92 | 2.21 ± 0.39 | 1.93 ± 0.50 | 1.24 ± 0.16 | 1.02 ± 0.48 |
| CL (L/h·m²) | 0.019 ± 0.00184 | 0.04 ± 0.01 | 0.014 ± 0.00567 | 0.01 ± 0.01 | 0.011 ± 0.0028 | 0.013 ± 0.005 | 0.0055 ± 0.0035 | 0.01 ± 0.01 |
| MRT (h) | 246.9 ± 45.76 | 152.71 ± 8.43 | 195.92 ± 49.96 | 184.46 ± 91.48 | 222.12 ± 73.58 | 187.96 ± 52.62 | 316.92 ± 188.21 | 58.64 ± 12.42 |

The results were confirmed by two other studies of the combination of rituximab with epratuzumab, totaling over 130 patients with NHL. The results showed that, in indolent lymphoma, this combined therapy is effective, ORs are durable and, most importantly, the report provided encouraging evidence that patients who achieved CRs experienced durable remission that appears to exceed those reported in other trials in patients with FL who were given the standard 4-week rituximab schedule. 25 In addition, clinical trials performed in DLBCL also showed encouraging results; a study reported that an OR rate of 47% (33% CR/CRu) was observed in 15 patients with DLBCL. Results from another trial combining these two antibodies with conventional CHOP therapy treating 15 previously untreated patients with DLBLC indicated an OR of 87% (67% CR, 20%
have been established in western Caucasian population, but patients with NHL. CD22 antigen might be a better choice to improve the efficacy in treatment resolved rapidly after G-CSF therapy. The connection between infusion reactions, epratuzumab is well tolerated when given at effects were observed in patients administered SM03. Apart from unfavorable compared with that observed for epratuzumab, i.e., more adverse effects occurrence and higher incidence rate of side effects were observed in patients administered SM03. Apart from infusion reactions, epratuzumab is well tolerated when given at doses of 120 to 1,000 mg/m²/week for four doses each over 1 h. In the present Phase 1 escalation study in Chinese patients with NHL, the side effects experienced in patients included fever, prostration, skin rash, hypotension, hypertension, fatigue, occult blood. However, most treatment-related toxicities were mild to moderate in severity excluding grade 4 lymphopenia and serious PT and APTT. The most frequent toxicity for all adverse events was infusion reactions (72%) that occurred predominately during the first infusion, with low-grade (mild-moderate) chills, rigors, fever to those observed previously in epratuzumab.

Patients treated with SM03 developed mild and generally reversible hematologic toxicity; 8 patients experienced grade 1/2 leukopenia and 4 patients developed grade 1/2 neutropenia, and all resolved without any therapy. However, a patient experienced grade 4 neutropenia 5 d, and resolved rapidly without G-CSF therapy, and etiology could not be found. An interesting result was observed in a patient who developed severe neutropenia 1 mo after each of two courses of rituximab therapy; the condition resolved rapidly after G-CSF therapy. The connection between B cells and myeloid maturation is not yet known. It has been noted that white cell disorders associated with rituximab were mainly classified as severe, the incidence of cytopenias of 25–40% in lymphopenia, 2–6% neutropenia, 4% leucopenia, 1–3% anemia and 1–2% thrombocytopenia. It is strange that myleosuppression toxicities were not observed in 103 patients treated with epratuzumab.

Elevated levels of aminotransferase were observed in six patients of 21 patients after SM03 administration; the severity was mild (grade 1 and 2) and reversible, with no correlation to administered dose. We did not observe hepatitis B virus (HBV) reactivation induced by SM03 in 3 patients who had been anti-HBs-positive and were treated with anti-viral drugs such as hep-todin, although their aminotransferase levels were elevated (1–2 times), and they resolved with no need for administration of hepatitis. According to literature reports, liver dysfunction was not observed in patients who were administered epratuzumab. However, 55% of patients who received rituximab therapy experienced liver failure, while the associated mortality rate was 48%. There were some reports showing that rituximab can induce HBV reactivation, in part relating to reduction of anti-HBV antibodies caused by rituximab and the associated host immunity balance. Further research will be done to monitor the anti-HBV surface antibody titers with SM03 therapy.

It is surprising that we observed prolonged prothrombin time in 9 patients because this effect was reported as rare after rituximab and epratuzumab therapy. Specially, a patient developed severe PT and APTT and showed low coagulation factors levels. The patient resolved rapidly after intravenous administration of coagulation factors. There is no known connection between B cells and prothrombin. Further research is needed to determine whether there are correlations between SM03 and disordered coagulative function, which may be induced by lymphoma itself or concomitant treatment (such as chemotherapy).

Side effects were not related to protein dose amount. No effects were seen on Ig levels or T cell counts. Because of relatively low baseline levels (likely related to previous therapy), the direct effect of SM03 on circulating B-cell levels could not be clearly determined in this study, which is similar to the results observed in patients given epratuzumab.

The clearance of SM03 is controlled by non-specific IgG clearance and irreversible binding to free B cells, and it is protected from endocytosis by recycling through the IgG salvage receptor FcRn. Target-mediated drug disposition (TMDD) is the main clearance pathway reported for therapeutic mAbs and is intimately linked to their high affinity and high specificity. The nonlinear kinetic caused by TMDD has substantial consequences on both preclinical and clinical study design, in particular on dose selection and dosing scheme. Thus, a common PK model for mAbs is the two-compartment model in which a saturable clearance is added to the linear clearance in the case of nonlinear kinetics. A recent review showed that nonlinear kinetics is reported for about half of the currently marketed mAbs. For example, cetuximab shows nonlinear elimination at doses ≥250 mg/m². At this dose, the binding of antibody to the epidermal growth factor receptor (EGFR) is saturated, and the dose of 250 mg/m² is recommended for clinical administration. It is generally accepted...
that target binding is closely linked to efficacy, and the saturation of the clearance implies the saturation of the target.

As a consequence of the saturable binding of SM03 to its target, a dose-dependent (nonlinear) elimination is observed. The pharmacokinetic profiles of SM03 indicated that disposition was nonlinear and was associated with an increase in drug exposure with increasing dose or number doses. The AUC of SM03 in Chinese patients was 16.81 mg·h/L and 41.52 mg·h/L at doses of 360 and 480 mg/m², respectively, which is lower than that of non-Chinese patients administered epratuzumab (AUC of 46.5 and 72.5 mg·h/L respectively at the doses of 360 and 480 mg/m²). In the study presented here, clearance appeared to decrease by 3.4 times with doses from 120 to 480 mg/m²/week, indicating the saturation of clearance at 480 mg/m² dose. It is widely believed that antibodies accumulate primarily in the circulation system and only to a low level in extracellular fluid and tissue with their distribution volume of about 4–5 L. The theoretical calculation of \( C_{\text{max}} \) (according to the formula \( C_{\text{max}} = \text{amount of drug/distribution volume} \)) was 38.4, 76.8, 153.6, 230.4, 307.2 \( \mu \)g/L at respective doses after the first administration, which was in accordance with the measured peak concentration excluding the 480 mg/m² dose. After administration of 4 doses, the ratio of the amount of SM03 binding to CD22 antigen and the total amount of SM03 were 80, 70, 60, 50, ~0% at different dosage, a result demonstrating the saturation binding of antigen at 480 mg/m² dose, and therefore the maximum anti-tumor effect would be expected to be reached at the 480 mg/m² dose. The extended half-life of SM03 also indicates that less frequent dosing schedules may be feasible. Tumor burden was observed to relate to clearance, i.e., clearance of patients carrying less tumor burden was lower than that of patients carrying moderate or huge tumor burden.

A previous clinical study of epratuzumab showed a significant number of objective tumor responses, with a total of nine of 51 assessable patients achieving OR after 4 once-weekly infusions of epratuzumab. In another Phase 1/2 clinical study of epratuzumab in NHL, five of 52 evaluable NHL patients achieved an OR (three CR and two PR), and 12 patients had stable disease and 35 progressed. Across all histologies, 20% of patients experienced anti-lymphoma activity as measured by reduction in tumor mass. However, in the study presented here, no objective

### Table 5. Changes in IgA, IgG and IgM before and after treatment in 21 patients

|          | Baseline (g/l) | Day 7 (g/l) | Day 14 (g/l) | Day 21 (g/l) | Day 28 (g/l) |
|----------|----------------|-------------|--------------|--------------|--------------|
| IgA      | 1.20 ± 0.70    | 1.18 ± 0.64 | 1.23 ± 0.71  | 1.21 ± 0.67  | 1.22 ± 0.79  |
| IgG      | 10.53 ± 4.60   | 9.10 ± 3.55 | 9.65 ± 4.02  | 9.52 ± 3.84  | 9.67 ± 3.79  |
| IgM      | 0.82 ± 0.50    | 0.72 ± 0.49 | 0.76 ± 0.49  | 0.74 ± 0.50  | 0.71 ± 0.41  |

**Figure 4.** Post-treatment changes in peripheral B-cell counts (n = 21). B-cell levels as measured by CD19+ cell count decreased by 30–70% from baseline up to 42 d at dose 360 and 480 mg/m²/week.
lower tumor burden and normal LDH tended to be more likely to respond to antibodies targeting CD22, and these characteristics are also associated with other anti-lymphoma agents.

In conclusion, the results from this Phase 1 study suggest that SM03 is safe, acceptably tolerated, and shows potential efficacy in Chinese patients with FL. When this is analyzed in conjunction with the pharmacokinetic data, which showed evidence of saturation of clearance at the 480 mg/m² dose, the implication was that further studies could focus on doses of 480 mg/m²/week. Phase 2 clinical trials evaluating SM03 combined with CHOP standard regimens in treating Chinese patients with NHL are now in progress.

Materials and Methods

SM03. SM03 is a recombinant, human/mouse chimeric IgG1 mAb directed against the extracellular domain of CD22 on human B lymphocytes. It is different from epratuzumab, a humanized IgG1, in amino acid sequence. However, SM03 targets the same epitope domain of CD22 as epratuzumab. Preclinical trial studies show that SM03 effectively removes B cells in the peripheral blood of macaque and cynomolgus, and does not induce any anti-SM03 antibodies in cynomolgus after weekly administration of SM03 at doses of 373.1 mg/m², 1,119.4 mg/m² or 3,358.2 mg/m² consecutively for 12 weeks (data not shown). SM03 is produced in ST20 cells, which is a stably transfected murine myeloma cell line (SP2/0). The chimeric antibody is encoded from the variable region (Fab domain) cDNAs of the murine anti-human CD22 mAb and the cDNAs for human kappa and gamma 1 constant regions (Fc domain). SM03 is produced by cell culture in bioreactors, using serum-free media, at Lonn Ryon Pharma Ltd., (Shenzhen, China).

After clarification, the concentrated solution was purified through a series of chromatographic steps, resolved in potassium phosphate buffer solution (pH 7.2) containing polysorbate 80, vialled under aseptic conditions and formulated as a colorless, sterile product without any preservatives.

Study design. This study was an open-label, Phase 1 study conducted at Sun Yat-sen University Cancer Center and designed to evaluate the safety, pharmacokinetic and antitumor effects of SM03 therapy. All subjects gave written informed consent before participating in study-related procedures. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the ethical and quality standards of good clinical practice, and all applicable regulatory requirements and laws. Infusions were administered once weekly for 4 consecutive weeks at doses from 60 mg/m² to 480 mg/m². The study consisted of a screening period (within 21 d before day 1),
an inpatient treatment period (days 1 to 28), and an outpatient period (days 29 to 42).

 Patients. Patients were eligible for enrollment if they had a diagnosis of CD22-positive B NHL, according to the World Health Organization (WHO) classification, version 2. Patients were included if they had progressed after at least one or two chemotherapy regimens, which included anthracycline or anthraquinone for aggressive B NHL. Other inclusion criteria were age ≥18 and ≤70 y, a performance status of one or better on the eastern Cooperative Oncology Group Scale, life expectancy ≥12 weeks, an absolute neutrophil count (ANC) ≥1.5 x 10^9/L and platelet count ≥100 x 10^9/L, serum creatinine ≤1.5x upper limit of normal (ULN), urine protein-to-creatinine ratio of ≤0.2, total bilirubin ≤1.5x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN and at least one measurable lesion ≥1.5 cm in at least one dimension by computer tomography (CT) at inclusion, in an area of no prior radiation therapy, or clear progression in an area that had been previously irradiated.

 Study drug administration. SM03 (chimeric IgG1 anti-CD22 mAb) was produced and quality-controlled at Shenzhen Lonn Ryonn Pharmaceutical Co., Ltd. (Shenzhen, Guangdong province, China) and administered by intravenous infusion at doses of 60, 120, 240, 360, 480 mg/m^2/week for 4 consecutive weeks with 42 d cycle. Each dose of SM03 in 250 ml 0.9% sterile NaCl was prepared by the hospital pharmacy (Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong province, China) and was to be administered throughout a 3 h period. To minimize hypersensitivity, patients were premedicated with acetaminophen (0.5–1 g) and antihistamine (25–50 mg per os or intravenous polaramine). Because clinical activity of epratuzumab in the treatment of NHL was at doses of ≥240 mg/m^2 without any DLT at doses from 120 to 1,000 mg/m^2 and the recommended dose was 360 mg/m^2 for further evaluation, SM03 dose escalation was stopped if two patients experienced dose limited toxicity (DLT) and dose escalation to next dose if one patient experienced DLT 19. Dose escalation was halted at 480 mg/m^2 according to the clinical trial instruction of SM03 informed by State Food and drug Administration of China and additional patients were treated at dose level of ≥240 mg/m^2 to further assess efficacy.

 A DLT was defined as any of the following that were at least possibly related to SM03 during the first 42 d after the first dose: any grade 3 or 4 [National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC), version 3] nonhematologic toxicity (except grade 3 alopecia, nausea or vomiting unless the patient was receiving optimal medical therapy); febrile neutropenia (grade 4 ANC ≥3-d duration and temperature ≥38); grade 4 ANC ≥7-d duration; grade 4 thrombocytopenia ≥5-d duration, or any bleeding episode requiring platelet transfusion. Patients who experienced a DLT were not to receive the additional cycles of SM03 at the same dose. The maximum number of doses of SM03 was 6 for 240 mg/m^2, 360 mg/m^2, 480 mg/m^2.

 Clinical assessment and safety. Clinical assessment consisted of vital pathological signs monitoring (before and every 15 min during infusion); general laboratory examination (screening, every week and at restaging); hematology tests, hepatic function tests, renal tests and immunoglobulin tests (screening, every week and at restaging), T-cell amounts, B-cell amounts, Ig levels (screening, every week and at restaging) Version 3.0 of the NCI Common Terminology Criteria for Adverse Events (AE) was used for toxicity and AE reporting. AEs were recorded throughout the study and graded according to the NCI CTC, and were considered to be treatment emergent if onset occurred between the first and the last dose, plus a lag of 42 d provided the following criteria were: (i) the AE was not present before the start of the first dose and did not occur in the patients as a chronic condition; (ii) the AE was present before the start of the first dose or as part of the patient’s medical history, but the severity or frequency increased after the start of the first dose. Patients were evaluated for response 3 weeks after the last infusion.

 Pharmacokinetics. Blood samples were taken for determination of serum SM03 concentrations on days 1 and 22 before dosing, and at 1, 2, 3 (2 min before the end of the SM03 infusion), 2.5, 4, 8, 24, 48, 72, 120 and 144 h after dosing, and on day 8 and 15 before dosing and at 3, 24, 72, 144 h after dosing. SM03 concentration was used an anti-SM03 idotype LRID03 adsorbed onto a microtiter plate to capture SM03 in 0.01% serum. The captured SM03 was detected using a peroxidase-conjugated AffiniPure horseradish polyclonal anti-human IgG Fcγ fragment reagent. The assay has a calibration range of 0.19 to 200 ng/ml in 0.01% serum; the lower limit of quantification was determined to be 0.19 ng/ml. Deviations of the predicted concentrations from the nominal values for the quality control samples were within 12.3%. The inter-run and intra-run variability estimates were within 5.0–9.6% and 8.0–11.0% coefficient of variation (CV), respectively.

 The non-compartmental pharmacokinetic parameters of SM03 were estimated using the WinNonlin (version 5.0) program. The parameters determined included the following: end-of-peak concentration (C_{max}), area under steady-state distribution (V_{ss}) and the terminal-phase elimination half-life (t_{1/2}).

 HAHA assay. Blood samples were collected within 1 week before study entry, 24 h after the first and the last infusion and at restaging to test for the presence of human antihuman antibodies (HAHAs). This assay was developed by Shenzhen Lonn Ryonn Pharmaceutical Co., Ltd., using an enzyme-linked immunosorbent assay with a lower level of detection of 50 ng/ml.

 Efficacy. Patients were evaluable for efficacy at day 42 with CT scan. Tumor response was assessed according to the International Workshop Response Criteria for non-Hodgkin Lymphoma. The overall response rate (ORR) was defined as the percentage of patients meeting the criteria for complete response (CR), unconfirmed complete (CRu) or partial response (PR). Stable disease (SD) was measured from the start of the treatment until the criteria for PD were met, taking as the reference the smallest measurements recorded since the initiation of the treatment.

 Statistical analysis. In general, discrete variables, including responder rates and AEs, were summarized using frequency counts and percentages. Percentage changes in individual efficacy parameters, B- and T-cell counts, Igs, duration of infusion times, and other continuous numerical variables were summarized using descriptive statistics. The Wilcoxon signed rank
The study was sponsored in full by Zhending Li (Shenzhen Lonn Ronnn Pharmaceutical Co., Ltd., Shenzhen, Guangdong province, China).

Acknowledgments

The authors would like to thank Dongshen Zhang (Sun Yat-sen University, Cancer Center) for editing the manuscript and for logistics of submission and Dr. Wenqi Jiang (Sun Yat-sen University, Cancer Center) for discussions.

References

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52:23-47; PMID:11814064; http://dx.doi.org/10.3322/canjclin.52.1.23.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Arlie House, Virginia, November 1999. Hematol J 2000; 1:53-66; PMID:11920170; http://dx.doi.org/10.1038/sj.hj.3900013.
3. Maltani P, White CA, Grillo-Lopez A, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol 2001; 2:279-91; PMID:11762410; http://dx.doi.org/10.2174/1389201013378567.
4. Fisher RI. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. Semin Oncol 2000; 27:2-8; PMID:11225596.
5. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second-generation combination chemotherapy regimen (m-BAcisD) with a standard regimen (CEOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342-9; PMID:1383819; http://dx.doi.org/10.1056/NEJM199211051327093.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Cinczak MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735.
7. Coiffrer B, Haouas C, Kertzer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20) monoclonal antibody for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-32; PMID:9731049.
8. Turner A. Antibodies. In: Roitt I, Brostoff J, Male D, Editors. Immunology. New York: Mosby 2001; 65-86.
9. Lundin J, Otterberg A, Börtinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphoma: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16:3257-63; PMID:9799699.
10. Fayad L, Patel H, Verhoef G. Clinical activity of the immunonconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study. Blood 2006; 108:2711.
11. Dijoseph JP, Armellino DC, Bogaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunonconjugate of calicheamicin for the treatment of relapsed or refractory malignant lymphoma. Blood 2004; 103:1807-14; PMID:14615373; http://dx.doi.org/10.1182/blood-2003-07-2466.
12. Clark EA, CD22, A B-cell-specific receptor, mediates adhesion and signal transduction. J Immunol 1993; 150:4715-8; PMID:8495506.
36. Fracasso PM, Burris H, 3rd, Arquette MA, Govindan R, Gao F, Wight LP, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13:986-93; PMID:17289894; http://dx.doi.org/10.1158/1078-0432.CCR-06-1542.